asininityandbeyond (@asininitybeyond) profile picture
Joined March 2018
Photo by asininityandbeyond (@asininitybeyond)Photo by asininityandbeyond (@asininitybeyond)Photo by asininityandbeyond (@asininitybeyond)Photo by asininityandbeyond (@asininitybeyond)Photo by asininityandbeyond (@asininitybeyond)Photo by asininityandbeyond (@asininitybeyond)Photo by asininityandbeyond (@asininitybeyond)Photo by asininityandbeyond (@asininitybeyond)Photo by asininityandbeyond (@asininitybeyond)Photo by asininityandbeyond (@asininitybeyond)
Have to admit to be being disappointed about the prospect of another placing. Remains my view the IP is mature enough to monetise but, admittedly, I don’t know what is playing out behind closed doors. Expect this is a brief trading pause + there is plenty of demand.1/2 #AVCT
Agreed Been of the view for a while now that we’ve passed the point where the business needs to be equity funded, as there is sufficient progress and scope across the IP (and resulting products) to now monetise the technology Which is, in my view, more shareholder friendly
1
21
4,983
In other #AVCT news ⬇️ Surely nodding at more than a hint of efficacy in AVA6103? The key clinical activity and, therefore, validation in H1 being the FOCUS trial. Doesn’t make sense for this comment to relate to A6K, IMO. Many have assumed AVA6103 efficacy, now confirmed? 2/2
25
1,253
Astonishing safety comparisons with Enhertu, which did $1.4bn revenue in Q1 26. The usual mention partnering, inflection points etc. We are talking serious, scaled deals given what is in the data. “Pipeline expansion”… left field… watch this space IMO 1/2 #AVCT
1
6
56
3,285
Back to 6103, the fact the below statement precedes the pre-clinical efficacy comparison with Enhertu, says it all really: preclinical PK = modelled deep and prolonged partial responses ➡️ observed patient PK = patient anti tumour activity Read between the lines 2/2 #AVCT
1
28
1,794
Vesting conditions - 6103 readout makes sense. 6207 candidate selection has been signposted Not sure if intended to be sequential but, if so, new IND filing between the above is curious. It would logically follow the last item if 6207 related Something left field in play? #AVCT
1
44
2,899
Venk “oversaw all worldwide commercial + technical operations as well as managing the company's P&L until the successful acquisition of Cubist by $MRK” A $9.5bn transaction in 2014 money. A huge deal A proper pharma operator who has trod the path #AVCT is about to follow, IMO
1
5
82
3,027
“Navigating finances, operations + *deals*” All crucial to #AVCT’s journey but there is growing expectation around delivery of commercial deal(s) + the co seems v aware of this Right deals at the right time AVA6103 + platform validation narrative cements TO in due course, IMO
We are thrilled to welcome Patrick to the Board at #AVCT. His deep sector experience building companies and navigating finances, operations and deals on both sides of the Atlantic will be critical for us at this time. #LetsDoThis #HopeWithoutCompromise
1
2
28
2,493
An incredible development + hugely positive that #AVCT is now willing to state it so clearly: “Two analyses both demonstrate no relationship between the level of FAP expression & degree of tumor response.” Boldness superseded only by an RNS titled “PLATFORM-VALIDATING DATA”!
1
7
88
2,164
AVA6000 patient population is getting increasingly meaningful Acknowledgment of this full ‘n’ group further supports my view that accelerated pathways for SGC (and maybe others) leverage the strong safety of the full trial, beyond just indication subsets Very positive IMO #AVCT
1
3
44
2,484
Been busy with the day job recently but lots of positives coming from #AVCT now. This CEO statement is incredible. Confidence abounds + much to parse from these 4 paragraphs alone! Growing IP, rapid development, multiple commercial opps, broadening application of the tech.1/3
1
5
61
2,422
However the root of all value is here: “we believe [pre|CISION] is the only technology that is capable of delivering cancer treatment drugs directly to the tumor at the precise concentrations our payloads can achieve – and without triggering severe toxic side effects.” 2/3 #AVCT
2
4
42
1,440
Everything falls into place from this statement Its built on lab data. Informed by the success of A6K. It points to AVA6103 doing what we, co, Drs + patients all hoped Its not over-confidence but an informed articulation of what #AVCT holds + how it should be valued (by BP).3/3
44
1,494
Science day… Same old, same old? Maybe share price-wise but more meaningful in terms of intangibles, IMO. My first time at an #AVCT investor meeting in person - I live at least one border away from Piccadilly! Overall, lots of familiar content but some key additions. 1/6
2
3
66
4,182
- Richard Hughes was there facing off with investors… it’s a Science Day, he didn’t need to be. Easy to tell ppl they should get to meetings in person but I know myself it’s hard for many. So my somewhat independent take on #AVCT’s Science Day is: 5/6
1
3
45
3,186
✅ #AVCT’s tech is dynamite ✅ Team is absurdly talented ✅ there’s a maturity to (pre)clinical + commercial progress ✅ taking time to do it right will pay back ✅ FDA = a friendly counterparty ✅ independent doctors are excited about 6103 ✅ Nearterm: data + IP (+ deals?) 6/6
5
2
127
2,220
Its becoming more likely #AVCT is setting up for a Cancer of Unknown Primary (CUP) component to the AVA6103 trial in Ph2 IMO Suite of indications proving broad efficacy supports that, coupled with in-scope adeno + SC carcinoma histologies making up the majority of CUP cases.1/3
Replying to @asininitybeyond
It must be understood how critical tumour agnostic Tx is for rare cancer, cancer of unknown primary etc. As well as economic + practical benefits That preclin data shows the potential of 6103 across a range of indications, really bolstering those tumour agnostic credentials. 3/4
1
4
40
4,059
CUP has massive unmet need + with no specific Tx. A drug with the ability to target a range of indications based on FAP + a broad utility warhead like EXd is perfect for this. Opens up ODD, accelerated pathways for AVA6103, plus a big Ph2 patient population.2/3 #AVCT
1
29
1,519
Interestingly, 6103 poster refers to DU145 prostate cancer; a PSA + PMSA negative subtype, so traditional Tx dont work. AVA6103 presents opportunity for primary + CUP Staggering potential here - CUP success is both hugely lucrative + the pinnacle of platform valuation. 3/3 #AVCT
1
1
40
1,577